Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Biosimilars: Expanded Treatment Options

Joan M. Von Feldt, MD, MSEd, FACR, FACP  |  Issue: May 2016  |  

Education: The ACR will take an active role in helping the FDA educate stakeholders about biosimilars. We will work with other specialty groups, industry, pharmacy associations and other stakeholders to guide long-term, post-marketing assessments of biosimilars. We will share our experience and viewpoints to help shape new policies.

As biosimilars become part of our treatment plans, rheumatologists and rheumatology health professionals should be proactive in tracking them for safety and efficacy through clinical trials or registries. I know you must have many questions about biosimilars, and your patients may be coming to you with questions of their own. Check for updates. Get involved with the ACR’s advocacy efforts, including in your own state. If you haven’t been involved in the ACR’s advocacy efforts before, now is a great time to start. Contact the ACR.

ADVERTISEMENT
SCROLL TO CONTINUE

Joan M. Von Feldt, MD, MSEd, FACR, FACPJoan M. Von Feldt, MD, MSEd, FACR, FACP, is president of the ACR and a professor of medicine at the Perelman School of Medicine at the University of Pennsylvania. She is also staff physician at the Philadelphia VA Medical Center.

Reference

  1. Covic A, Abraham I. State-of-the-art biosimilar erythropoietins in the management of renal anemia: Lessons learned from Europe and implications for US nephrologists. Int Urol Nephrol. 2015 Sep;47(9):1529–1539.

Related Articles
    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

    Possible Impact of Biosimilar Infliximab on U.S. Market in Prescriptions, Pricing

    The use of biosimilars for rheuma­tology in the U.S. became a reality when the U.S. Food and Drug Administration (FDA) approved Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), in April. What this may mean is increased competition among drug companies with regard to pricing and, therefore, potentially lower costs for U.S. patients, according to Seoyoung…